Impax Asset Management Group plc Raises Position in Enfusion, Inc. (NYSE:ENFN)

Impax Asset Management Group plc increased its holdings in Enfusion, Inc. (NYSE:ENFN) by 31.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 890,000 shares of the company’s stock after purchasing an additional 213,052 shares during the quarter. Impax Asset Management Group plc owned 0.69% of Enfusion worth $9,167,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in ENFN. New York State Common Retirement Fund grew its holdings in Enfusion by 23.8% in the 4th quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock worth $19,848,000 after acquiring an additional 370,498 shares during the last quarter. Rhumbline Advisers grew its holdings in Enfusion by 3.0% in the 4th quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock worth $643,000 after acquiring an additional 1,796 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Enfusion by 612.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock worth $1,974,000 after acquiring an additional 178,821 shares during the last quarter. Barclays PLC grew its holdings in Enfusion by 251.4% in the 3rd quarter. Barclays PLC now owns 86,039 shares of the company’s stock worth $817,000 after acquiring an additional 61,554 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Enfusion by 7.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock worth $9,770,000 after acquiring an additional 70,367 shares during the last quarter. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Insider Activity

In related news, CFO Bradley Herring sold 24,443 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $10.61, for a total transaction of $259,340.23. Following the sale, the chief financial officer now owns 270,503 shares of the company’s stock, valued at $2,870,036.83. The trade was a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.03, for a total transaction of $218,664.03. Following the sale, the chief operating officer now directly owns 1,143,544 shares in the company, valued at $11,469,746.32. The trade was a 1.87 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 57,367 shares of company stock valued at $591,335. Corporate insiders own 36.44% of the company’s stock.

Enfusion Trading Down 0.4 %

Shares of ENFN opened at $11.46 on Tuesday. The firm’s 50-day moving average price is $10.84 and its 200-day moving average price is $9.69. The firm has a market capitalization of $1.47 billion, a price-to-earnings ratio of 286.45, a PEG ratio of 1.85 and a beta of 0.96. Enfusion, Inc. has a 1-year low of $7.83 and a 1-year high of $11.80.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ENFN. William Blair reissued a “market perform” rating on shares of Enfusion in a report on Monday, January 13th. Piper Sandler raised their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Finally, Stifel Nicolaus raised their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $10.50.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.